Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

被引：0
|
作者：
Allen, Pamela B. [1 ]
Bazzi, Latifa [2 ]
Zhang, Bin [3 ]
Chen, Qing [4 ]
Slonim, Liron Barnea [4 ]
Savas, Hatice [5 ]
Advani, Ranjana H. [6 ]
Evens, Andrew M. [7 ]
Pro, Barbara [8 ]
Karmali, Reem [9 ]
Mou, Eric [10 ]
Eisner, Robert [11 ]
Bayer, Robert [11 ]
Gordon, Leo I. [12 ]
Winter, Jane N. [13 ]
机构：
[1] Emory Univ, Dept Hematol, Sch Med, Decatur, GA USA
[2] Northwestern, Biostatist, Chicago, IL USA
[3] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol & Oncol, Chicago, IL USA
[4] Northwestern Hosp, Pathol, Chicago, IL USA
[5] Northwestern, Radiol, Chicago, IL USA
[6] Stanford Univ, Dept Med, Div Oncol & Hematol, Stanford, CA USA
[7] Rutgers Canc Inst, New Brunswick, NJ USA
[8] Columbia Univ, Lymphoma Program, Div Hematol & Oncol, New York, NY USA
[9] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[10] Univ Iowa, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA USA
[11] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[12] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA
[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208680
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1664 / 1665
页数：2
相关论文
共 27 条
  • [1] Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis
    Allen, Pamela
    Chen, Qing C.
    Lu, Xinyan
    O'Shea, Kaitlyn
    Chmiel, Joan
    Sukhanova, Madina
    Slonim, Liron Barnea
    Savas, Hatice
    Mou, Eric
    Pro, Barbara
    Evens, Andrew M.
    Palmer, Brett Alan
    Advani, Ranjana
    Gordon, Leo I.
    Winter, Jane N.
    BLOOD, 2021, 138
  • [2] PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy
    Allen, Pamela B.
    Lu, Xinyan
    Chen, Qing C.
    Slonim, Liron Barnea
    Sukhanova, Madina
    Savas, Hatice
    Chmiel, Joan
    O'Shea, Kaitlyn
    Evens, Andrew M.
    Advani, Ranjana
    Pro, Barbara
    Karmali, Reem
    Palmer, Brett Alan
    Bearden, Jeffrey
    Mou, Eric
    Dillehay, Gary
    Gordon, Leo I.
    Winter, Jane N.
    BLOOD, 2020, 136
  • [3] Frontline Treatment With Single- Agent Pembrolizumab Followed by AVD Chemotherapy for Classical Hodgkin Lymphoma: Updated Results and Correlative Analysis
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 3 - 4
  • [4] Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab plus AVD for Classic Hodgkin Lymphoma
    Kuczmarski, Thomas M.
    Ujjani, Chaitra S.
    Poh, Christina
    Warren, Edus H.
    Smith, Stephen D.
    Shadman, Mazyar
    Till, Brian G.
    Raghunathan, Vikram
    Tseng, Yolanda
    Du, Hongyan
    Vandermeer, Jacquelin
    Kelly, Alyssa
    Rasmussen, Heather
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    Lynch, Ryan C.
    BLOOD, 2024, 144 : 1667 - 1668
  • [5] Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab plus AVD in Untreated Classic Hodgkin Lymphoma
    Kuczmarski, Thomas M.
    Ujjani, Chaitra S.
    Poh, Christina
    Warren, Edus H.
    Smith, Stephen D.
    Shadman, Mazyar
    Till, Brian G.
    Raghunathan, Vikram
    Tseng, Yolanda D.
    Du, Hongyan
    Vandermeer, Jacquelin
    Kelly, Alyssa
    Rasmussen, Heather
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    Lynch, Ryan C.
    BLOOD, 2024, 144 : 1666 - 1667
  • [6] Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study
    Ben Barouch, Sharon
    Bhella, Sita
    Kridel, Robert
    Kukreti, Vishel
    Prica, Anca
    Crump, Michel
    Kuruvilla, John
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1879 - 1886
  • [7] PENPULIMAB FOR RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN'S LYMPHOMA (CHL): EXTENDED FOLLOW-UP OF THE MULTICENTER, SINGLE-ARM, PHASE 2 STUDY
    Song, Yuqin
    Zhou, Keshu
    Jin, Chuan
    Qian, Zhengzi
    Hou, Ming
    Fan, Lei
    Li, Fei
    Ding, Kaiyang
    Zhou, Hui
    Li, Xiaoling
    Chen, Bing
    Sun, Xiuhua
    Song, Xianmin
    Jiang, Ming
    Zhang, Qingyuan
    Liu, Lihong
    Yu, Guohua
    Hu, Yu
    Zhao, Zheng
    Liu, Ligen
    Xue, Hongwei
    Luo, Jun
    He, Bai
    Yao, Zhifang
    Xu, Fenghua
    Zhao, Min
    Li, Baiyong
    Xia, Yu
    Zhu, Jun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A598 - A598
  • [8] Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
    Momotow, Jesko
    Goergen, Helen
    Behringer, Karolin
    Broeckelmann, Paul J.
    Borchmann, Sven
    Tresckow, Bastian V.
    Kobe, Carsten
    Engert, Andreas
    Sasse, Stephanie
    HEMASPHERE, 2019, 3 (05):
  • [9] Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039)
    Ansell, Stephen
    Armand, Philippe
    Timmerman, John M.
    Shipp, Margaret A.
    Garelik, M. Brigid Bradley
    Zhu, Lili
    Lesokhin, Alexander M.
    BLOOD, 2015, 126 (23)
  • [10] Intensive time-extended multi-agent chemotherapy followed by autologous haematopoietic stem cell transplantation for refractory or relapsed Hodgkin's lymphoma - Long-term results in 33 patients from a single centre
    Kata, D.
    Czerw, T.
    Sadus-Wojciechowska, M.
    Markiewicz, M.
    Krawczyk-Kulis, M.
    Wojnar, J.
    Dadok, J.
    Jakubowski, M.
    Helbig, G.
    Kyrcz-Krzemien, S.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S385 - S386
123